What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 3, 2025Open Access

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis

MKMotoki KanekoRush University Medical Center ASAtsushi SakurabaRush University Medical Center

Puntos clave

Inhibitors showed improved clinical outcomes in treating Crohn's disease, with varied efficacy and safety profiles.
Systematic review identified key differences among IL-23 inhibitors, focusing on inflammation management and treatment responses.
Therapeutic targets include drug efficacy and safety in moderate-to-severe Crohn's patients, guiding personalized treatment approaches.
Findings suggest a need for continued assessment in immunology to optimize biologic therapy in clinical practice.

Resumen

This is the first NMA comparing IL-23 inhibitors using contemporary evidence. The results offer practical insights for personalized CD treatment: guselkumab may be preferred for rapid response, mirikizumab for safety, and risankizumab for balanced efficacy.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo